KLS:7148

Duopharma Biotech Berhad · KLS · Healthcare · MYR · FY for 2025

Figures on this page computed 2026-11-08 13:20 UTC

Last close

n/aMYR

Market data

12.2xP/E
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
MYR
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
9.4%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
9.2%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
MYR
- Computed from the filing for 2025
- Computed from the filing for 2025
3.1%Dividend yield
Source
computed
Taken on
2026-11-08
Reported in
MYR
- computed

6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.

Follow one ringgit

lens 1 of 9

After what it costs to make

39.0%

After running the business

15.7%

After interest and tax

9.4%

After what it must reinvest

9.2%

Kept after the dividend

5.6%

after what it costs to make, 39.0% of sales; after running the business, 15.7% of sales; after interest and tax, 9.4% of sales; after what it must reinvest, 9.2% of sales; kept after the dividend, 5.6% of sales

The five stops

5 of 5 read

After what it costs to make363,137,00039.0%
After running the business146,491,00015.7%
After interest and tax87,463,0009.4%
After what it must reinvest85,954,0009.2%
Kept after the dividend52,286,0005.6%

Of every unit of sales, 0.06 is still there after the dividend.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales931,692,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
After what it costs to make363,137,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
After running the business146,491,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
After interest and tax87,463,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
After what it must reinvest85,954,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR
Kept after the dividend52,286,000
Source
computed
Statement
income
Fiscal year
2025
Reported in
MYR